NBIX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Neurocrine Biosciences, Inc (NBIX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong pipeline, positive analyst sentiment, and recent clinical successes provide a solid foundation for growth. While the technical indicators are neutral to slightly bearish in the short term, the long-term growth potential outweighs these concerns.
The MACD histogram is negative and expanding (-1.359), indicating bearish momentum. RSI is at 43.885, which is neutral but leaning towards oversold territory. Moving averages are converging, showing no clear trend. Key support is at $156.474, and resistance is at $161.856. The stock is trading near its support level, which could present a buying opportunity for long-term investors.
Positive clinical trial results for VYKAT XR and CRENESSITY, showcasing long-term efficacy and safety.
Analysts have raised price targets, with the highest target at $246, reflecting strong confidence in the company's growth prospects.
The acquisition of Soleno Therapeutics adds a third commercial product, enhancing revenue streams.
Short-term technical indicators suggest bearish momentum.
No recent significant insider or hedge fund activity, indicating a lack of strong institutional conviction in the short term.
No financial data available for the latest quarter. However, analysts have highlighted strong Q1 performance, with both Ingrezza and Crenessity sales exceeding expectations.
Analysts are overwhelmingly positive, with multiple firms raising price targets and maintaining Buy or Outperform ratings. The highest price target is $246, and the lowest is $155, indicating a consensus of significant upside potential.
